Venture

Platform technology to produce recombinant therapeutic antibodies against Staphylococcus aureus and other pathogens, targeting cell wall carbohydrates not adequately recognized by the human immune system.

Team:

Assaf Raz, PhD – CSO
Vincent A. Fischetti, PhD – Head of SAB